(Total Views: 390)
Posted On: 10/02/2017 8:02:40 PM
Post# of 72446
Re a question asked via PM: Brilacidin-OM should not be expensive or difficult to manufacture, especially as compared to biologics.
However I do not think that the company is going to be willing to license just ONE indication for Brilacidin. Let's say, for example, we have Brilacidin-OM as a rinse for oral mucositis. Then it's determined that Brilacidin-gingivitis oral rinse is a good idea, or Brilacidin rinse after oral surgery.
How do you differentiate licensing for an oral rinse for OM, and for gum disease, and for dental procedures? You can't.
My hope is that the company does NOT partner any one or even several Brilacidin formulations, but waits until many reach Phase III clinical trials, and then make a deal for the entire Brilacidin platform.
However I do not think that the company is going to be willing to license just ONE indication for Brilacidin. Let's say, for example, we have Brilacidin-OM as a rinse for oral mucositis. Then it's determined that Brilacidin-gingivitis oral rinse is a good idea, or Brilacidin rinse after oral surgery.
How do you differentiate licensing for an oral rinse for OM, and for gum disease, and for dental procedures? You can't.
My hope is that the company does NOT partner any one or even several Brilacidin formulations, but waits until many reach Phase III clinical trials, and then make a deal for the entire Brilacidin platform.
(3)
(0)
